Sanofi-Aventis has received a boost from the French agency which deals with reimbursement after it gave a favourable recommendation for the use of the firm’s obesity and diabetes drug rimonabant (Acomplia).
The Transparency Committee (Commission de la Transparence) has recommended that the government reimburse rimonabant for obese patients who are unable to control their type 2 diabetes with a monotherapy of metformin or a sulfonylurea, and who have an HBA1c level of between 6.5% and 10%. The committee has also suggested that the treatment should be combined with diet and physical activity.
